• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Centessa Pharmaceuticals plc

    2/14/22 8:07:51 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email
    SC 13G 1 d317626dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.     )*

     

     

    Centessa Pharmaceuticals plc

    (Name of Issuer)

     

     

    Ordinal Shares, nominal value £0.02 per share

    (Title of Class of Securities)

    152309100(1)

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (1)

    See Item 2(e).


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 2 of 8 Pages

     

     

      1.  

    NAMES OF REPORTING PERSONS

     

    Index Ventures Life VI (Jersey) L.P.

      2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Jersey, Channel Islands

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

         5.     

    SOLE VOTING POWER

     

    9,812,368 (1)

         6.   

    SHARED VOTING POWER

     

    0

         7.   

    SOLE DISPOSITIVE POWER

     

    9,812,368 (1)

         8.   

    SHARED DISPOSITIVE POWER

     

    0

      9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,812,368 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐

     

        

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    10.9% (1)

    12.  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    Index Ventures Life VI (Jersey) L.P. (“Index Ventures Life VI”) directly owns 9,812,368 Ordinary Shares of the Issuer, nominal value £0.002 per share (“Ordinary Shares”). The percent of class was calculated based on 89,900,916 Ordinary Shares outstanding as of November 15, 2021, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 3 of 8 Pages

     

     

      1.  

    NAMES OF REPORTING PERSONS

     

    Yucca (Jersey) SLP

      2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Jersey, Channel Islands

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

         5.     

    SOLE VOTING POWER

     

    149,421 (1)

         6.   

    SHARED VOTING POWER

     

    0

         7.   

    SOLE DISPOSITIVE POWER

     

    149,421 (1)

         8.   

    SHARED DISPOSITIVE POWER

     

    0

      9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    149,421 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐

     

        

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.2% (1)

    12.  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    Yucca (Jersey) SLP (“Yucca”) directly owns 149,421 Ordinary Shares of the Issuer. The percent of class was calculated based on 89,900,916 Ordinary Shares outstanding as of November 15, 2021, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 4 of 8 Pages

     

     

      1.

     

    NAMES OF REPORTING PERSONS

     

    Index Venture Life Associates VI Limited

      2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Jersey, Channel Islands

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

         5.     

    SOLE VOTING POWER

     

    9,961,789 (1)

         6.   

    SHARED VOTING POWER

     

    0

         7.   

    SOLE DISPOSITIVE POWER

     

    9,961,789 (1)

         8.   

    SHARED DISPOSITIVE POWER

     

    0

      9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,961,789 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐

     

        

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.1% (1)

    12.  

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)

    Index Venture Life Associates VI Limited (“Index Venture Life VI GP”) may be deemed to beneficially own the Ordinary Shares directly held by Index Ventures Life VI and Yucca. The percent of class was calculated based on 89,900,916 Ordinary Shares outstanding as of November 15, 2021, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 5 of 8 Pages

     

     

    Item 1.   Issuer

       (a)    Name of Issuer:
          Centessa Pharmaceuticals plc
       (b)    Address of Issuer’s Principal Executive Offices:
         

    3rd Floor, 1 Ashley Road

    Altrincham, Cheshire WA14 2DT

    United Kingdom

    Item 2.   Filing Person

       (a) – (c)    Name of Persons Filing; Address; Citizenship:
         

    (i)  Index Ventures Life VI, a Jersey, Channel Islands partnership.

         

    (ii)  Yucca, a Jersey, Channel Islands separate partnership.

         

    (iii)   Index Venture Life VI GP, a Jersey, Channel Islands corporation, the general partner of the Index Ventures Life VI.

          The address of the principal business office of each of the reporting persons is 44 Esplanade, St. Helier, Jersey, Channel Islands JE4 9WG.
          Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited act as sub-advisers to Index Ventures Life VI (Jersey) Limited, which acts as the adviser to Index Ventures Life VI, and as such, certain funds affiliated with Medicxi, which hold Ordinary Shares and/or Series A Preferred Shares as of the date hereof, and Index Ventures Life VI and Yucca, may be deemed to be members of a “group” as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended. The share ownership reported by the reporting persons does not include any shares beneficially owned by funds or other entities affiliated with Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited, and each of the reporting persons disclaim beneficial ownership of the securities beneficially owned by funds or other entities affiliated with Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited.
       (d)    Title of Class of Securities:
          Ordinary Shares, nominal value £0.002 per share
       (e)   

    CUSIP Number:

     

    CUSIP number 152309100 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer. Each ADS represents one Ordinary Share. No CUSIP number has been assigned to the Ordinary Shares of the Issuer.

    Item 3.   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

       (a)    ☐    Broker or dealer registered under Section 15 of the Act;
       (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
       (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
       (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
       (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 6 of 8 Pages

     

     

       (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
                    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 7 of 8 Pages

     

     

      

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Item 4.

       Ownership.
       (a) and (b)    Amount beneficially owned:
          (i)      Index Ventures Life VI directly owns 9,812,368 Ordinary Shares, which represents approximately 10.9% of the outstanding Ordinary Shares.
          (ii)      Yucca directly owns 149,421 Ordinary Shares, which represents approximately 0.2% of the outstanding Ordinary Shares. Yucca administers the co-investment vehicle that is contractually required to mirror the Index Ventures Life VI’s investments. As a result, Index Venture Life VI GP may be deemed to have dispositive and voting power over Yucca’s shares by virtue of its dispositive power over and voting power over the shares owned by the Index Ventures Life VI.
          (iv)      Index Venture Life VI GP may be deemed to beneficially own the 9,961,789 Ordinary Shares owned by Index Ventures Life VI and Yucca, which represents approximately 11.1% of the outstanding Ordinary Shares.
        (c)    Number of shares as to which such person has:

     

         Number of Ordinary Shares  

    Reporting Person

       (i)      (ii)      (iii)      (iv)  

    Index Ventures Life VI

         9,812,368        0        9,812,368        0  

    Yucca

         149,421           149,421     

    Index Venture Life VI GP

         9,961,789           9,961,789     

     

      

    (i)  Sole power to vote or direct the vote

     

    (ii)  Shared power to vote or to direct the vote

     

    (iii)   Sole power to dispose or to direct the disposition of

     

    (iv) Shared power to dispose or to direct the disposition of

       The percent of class was calculated based on 89,900,916 Ordinary Shares outstanding as of November 15, 2021, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.

    Item 5.

      

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6.

      

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

    Item 7.

      

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

    Item 8.

      

    Identification and Classification of Members of the Group.

     

    Not applicable.

    Item 9.

      

    Notice of Dissolution of Group.

     

    Not applicable.

    Item 10.

      

    Certification.

     

    Not applicable.


     

    CUSIP No. 152309100

     

       SCHEDULE 13G   

     

    Page 8 of 8 Pages

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    INDEX VENTURES LIFE VI (JERSEY) L.P.
    By:   Index Venture Life Associates VI Limited
    Its:   General Partner
    By:  

    /s/ Luke Aubert

      Name:   Luke Aubert
      Title:   Director
    YUCCA (JERSEY) SLP
    By:   Intertrust Employee Benefit Services Limited as authorized signatory of Yucca (Jersey) SLP in its capacity as an Administrator of the Index Co- Investment Scheme
    By:  

    /s/ Luke Aubert

      Name:   Luke Aubert
      Title:   Authorized Signatory
    By:  

    /s/ Genesis Perez

      Name:   Genesis Perez
      Title:   Authorized Signatory
    INDEX VENTURE LIFE ASSOCIATES VI LIMITED
    By:  

    /s/ Luke Aubert

      Name:   Luke Aubert
      Title:   Director
    Get the next $CNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTA

    DatePrice TargetRatingAnalyst
    5/8/2025$30.00Buy
    Chardan Capital Markets
    3/31/2025$38.00Overweight
    Piper Sandler
    1/7/2025Buy
    TD Cowen
    9/20/2024$11.00 → $26.00Equal-Weight → Overweight
    Morgan Stanley
    9/19/2024$33.00Buy
    B. Riley Securities
    7/18/2024$14.00Outperform
    Oppenheimer
    11/15/2023$4.00 → $11.00Hold → Buy
    Jefferies
    10/26/2023$4.00 → $8.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Cent

      3/24/25 7:00:49 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

      BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1

      3/6/25 4:14:40 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

      BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025Fireside Chat: 1:00 PM ET Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: February 12, 2025Fireside Chat: 10:40 AM ET Event: TD Cowen 45th Annual Health Care ConferenceDate: March 4, 2025Fireside Chat: 1:50 PM ET Event: Leerink Partners Global Healthcare ConferenceDate: March 11,

      1/28/25 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Centessa Pharmaceuticals plc

      DEF 14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/6/25 9:00:14 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Centessa Pharmaceuticals plc

      144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

      4/25/25 4:12:30 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Centessa Pharmaceuticals plc

      PRE 14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      4/22/25 4:59:12 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Centessa Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      5/8/25 8:28:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Centessa Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00

      3/31/25 8:13:04 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Centessa Pharmaceuticals

      TD Cowen initiated coverage of Centessa Pharmaceuticals with a rating of Buy

      1/7/25 7:47:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 5:43:48 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 4:20:32 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      2/14/24 5:37:34 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hussain Iqbal J exercised 311 units of Ordinary Shares at a strike of $5.84 and sold $4,354 worth of Ordinary Shares (311 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/2/25 4:17:05 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Hussain Iqbal J exercised 5,689 units of Ordinary Shares at a strike of $5.84 and sold $79,658 worth of Ordinary Shares (5,689 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      4/29/25 4:58:03 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Weinhoff Gregory M sold $159,857 worth of Ordinary Shares (11,742 units at $13.61), decreasing direct ownership by 9% to 122,279 units (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      4/25/25 8:20:27 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Financials

    Live finance-specific insights

    See more
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

      SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA

      11/13/23 4:05:10 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

      Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti

      8/14/23 7:00:30 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

      – Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals

      5/12/23 7:00:06 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

      BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

      1/8/25 7:05:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

      BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

      6/10/24 7:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

      BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

      10/3/23 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care